CorMedix Inc. (CRMD): M&A transaction — CorMedix completes $300M acquisition of Melinta; raises FY2025 revenue guidance

CorMedix Inc.

Acquisition closed Aug 29, 2025; $260M cash + $40M equity upfront, plus up to $25M in milestone payments.
Pro forma 2025 revenue guidance raised to $325-350M; synergies expected $35-45M annually.
Transaction expected near-term accretive to EPS with double-digit accretion in 2026.
Susan Blum appointed CFO, Elizabeth Hurlburt COO, Matthew David CBO effective immediately.
Contingent payments include tiered royalties on REZZAYO US net sales and low-single-digit royalties on MINOCIN US net sales.

item 1.01 item 2.01 item 3.02 item 5.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

CorMedix Inc. underwent a change of control involving Melinta Therapeutics, LLC for $260 million in cash and $40 million worth of common shares (closed 2025-08-29).

Action: change of control
Counterparty: Melinta Therapeutics, LLC
Consideration: $260 million in cash and $40 million worth of common shares
Closing: 2025-08-29

Exact text from the filing

at the effective time of the Merger (the “Effective Time”), the Company (i) paid to the Melinta equityholders (including the Consenting Melinta Members) an aggregate of $260 million in cash (subject to adjustment for the Aggregate Exercise Price, Estimated Company Cash, Estimated Company Debt, Estimated Working Capital as compared to the Working Capital

View on SEC.gov

Browse all m&a transactions →

CorMedix Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-082956

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.